Find a Clinical Trial

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

18+

Learn more

Feasibility of a new method for non-invasive monitoring of low-grade bladder cancer

Feasibility of a new method for non-invasive monitoring of low-grade bladder cancer

18-90

Learn more

TEE Assessment of PVR

Transesophageal Echocardiographic Assessment of Pulmonary Vascular Resistance

18+

Learn more